Loading...
•
Mar 31, 2021
Travere Q1 2021 Earnings Report
Reported first quarter financial results.
Key Takeaways
Travere Therapeutics reported net product sales of $47.4 million for the first quarter of 2021. The company is engaging with regulators in pursuit of submissions for accelerated approval for sparsentan in focal segmental glomerulosclerosis (FSGS).
Net product sales for the first quarter 2021 were $47.4 million.
The Phase 3 PROTECT Study of sparsentan in IgA nephropathy (IgAN) is nearing completion of patient enrollment and remains on-track to report topline data from the 36-week proteinuria analysis in the third quarter of 2021.
The Company is engaging with regulators in pursuit of submissions for accelerated approval.
Cash, cash equivalents and marketable securities, as of March 31, 2021, totaled $520.9 million
Forward Guidance
The Company continues to anticipate mid-single-digit percentage growth in net product sales compared to 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...